Childhood cancers: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 98
• TP53 8
• PD-1 24
• MYCN 0
• ALK 13
• CD22 30
• BRAF 12
• NF1 12
• ABL1 2
• HER2 25
• PI3K 5
• AKT 1
• CDK4/6 7
• PD-L1 13
• NTRK 10
• NMDA 0
• B7-H3 15
• mTOR 2
• RB1 1
• KMT2A 12
• PSMA 20
• MEK 7
• FLT3 6
• MAPK 5
• CD30 8
• RUNX1 3
• VEGF 5
• IDH 6
• MYC 1
• RET 4
• CD20 12
• ERK 0
• PTEN 2
• CD123 10
• NPM1 9
• EGFR 2
• CTNNB1 2
• FGFR 3
• STAT3 0
• BRCA1 1
• BCL-2 2
• KIT 3
• ROS1 9
• CD33 7
• NRF2 0
• PARP 6
• PPAR 0
• YAP 0
• RAS 1
• CD38 5
• EZH2 0
• JAK 4
• JNK 0
• SNCA 0
• BRCA2 2
• CTLA-4 4
• KRAS 3
• MET 4
• NRAS 0
• VHL 5

24 of 34+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia

  NCT07556757· ImmunityBio, Inc.· Updated 19 Aug 2026

  “Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug”Registry text, quoted unchanged. Source

• Suspended

  Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL

  NCT06985498· The First Affiliated Hospital of Soochow University· Updated 29 May 2026

  “According to the new regulations of China, newly launched clinical trials involved CAR-T cells must be apporved first by China National Center for Biotechology Development.”Registry text, quoted unchanged. Source

• Suspended

  Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

  NCT06662227· Wondercel Biotech (ShenZhen)· Updated 7 May 2026

  “Because the implementation of the new regulation policy by the Chinese authority”Registry text, quoted unchanged. Source

• Withdrawn

  Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma

  NCT07093086· Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd· Updated 6 May 2026

  “The primary consideration is the allocation of company resources, and we have no choice but to terminate this research.”Registry text, quoted unchanged. Source

• Terminated

  CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL

  NCT04049383· Medical College of Wisconsin· Updated 12 Jan 2026

  “Low accrual”Registry text, quoted unchanged. Source

• Withdrawn

  TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant

  NCT05968170· Neena Kapoor, M.D.· Updated 14 Jul 2025

  “No funding available.”Registry text, quoted unchanged. Source

• Withdrawn

  TCR Alpha/Beta and CD19-deplete Haplo-HSCT

  NCT05288595· University of Colorado, Denver· Updated 18 Oct 2024

  “Cancelled by Sponsor”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

  NCT03743246· Celgene· Updated 15 Aug 2024

  “Absence of significant therapeutic benefit over existing therapies”Registry text, quoted unchanged. Source

• Withdrawn

  Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

  NCT03098355· Zhujiang Hospital· Updated 18 Mar 2024

  “The company did not offer the appropriate CART services.”Registry text, quoted unchanged. Source

• Withdrawn

  CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma

  NCT05613348· Zhujiang Hospital· Updated 18 Mar 2024

  “The company failed to provide corresponding CART services.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  NCT07570173· Merck Sharp & Dohme LLC· Source

• Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

  NCT02315599· National Cancer Institute (NCI)· Source

• Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

  NCT03226704· National Cancer Institute (NCI)· Source

• CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

  NCT05442515· National Cancer Institute (NCI)· Source

• CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL

  NCT05440409· National Cancer Institute (NCI)· Source

• CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

  NCT05470777· The First Affiliated Hospital of Soochow University· Source

• CAR-T Cell Therapy for ALL

  NCT07695012· Dr. Zaineb Akram· Source

• CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia

  NCT03984968· The First Affiliated Hospital of Soochow University· Source

• A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies

  NCT07503353· Sheba Medical Center· Source

• CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

  NCT06847269· St. Jude Children's Research Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 38
• Organoids 15
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 15
• Gene Expression Profiling 125
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 22
• Exome Sequencing 31
• Proteomics 52
• Metabolomics 25
• Mass Spectrometry 13
• Flow Cytometry 87
• Immunohistochemistry 197
• Liquid Biopsy 25
• Circulating Tumor DNA 15
• Xenograft Model Antitumor Assays 134
• Positron-Emission Tomography 52
• Magnetic Resonance Imaging 522
• Machine Learning 69
• Deep Learning 25
• Cohort Studies 328
• Genome-Wide Association Study 22

• Clinically actionable genetic findings by exome sequencing performed for therapeutic purposes in children with very-high risk cancer included the MAPPYACTS study.

  Eur J Cancer, Oct 2026

• Genomic Characterization of RTK-RAS Pathway Alterations in Juvenile Myelomonocytic Leukemia Through Whole-Exome Sequencing.

  Med Sci (Basel), Sept 2026

  Aditya Kumar Gupta

• T-rex: standardized analysis of germline variants in whole-exome sequencing trios.

  Sci Rep, Aug 2026

• Clinical characteristics and variant spectrum of NF1 in Chinese patients with neurofibromatosis type 1: a cross-sectional study.

  Orphanet J Rare Dis, Aug 2026

• Effect of ARHGAP9 on Chemoresistance in High-Risk Advanced Retinoblastoma via the Rac1/β-Catenin/LEF1 Signaling Axis.

  Invest Ophthalmol Vis Sci, Aug 2026

• Novel Germline ELP1 Splice-Acceptor Variant in NF1-Negative Optic Pathway Glioma: Expanding the Clinical Spectrum Associated With ELP1 Variation.

  Clin Genet, Jul 2026

• Genetic Determinants of Treatment-Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia.

  Clin Pharmacol Ther, Jun 2026

• Genotypic and phenotypic features of 23 Egyptian patients with tuberous sclerosis complex.

  BMC Pediatr, Jun 2026

• Prenatal diagnosis of cardiac rhabdomyoma: implications for predicting tuberous sclerosis complex and guiding perinatal management.

  Ultrasound Obstet Gynecol, Jun 2026

• Expanding the spectrum of H3K27-altered gliomas: Hemispheric cases with midline epigenetic signatures.

  Ann Diagn Pathol, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.